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Abstract
Background: COVID-19 has affected global communities with multiple neurological complications in addition to other
critical medical issues. COVID-19 binds to the host’s angiotensin-converting enzyme 2 (ACE2) receptors, which are
expressed in the neurons and glial cells, acting as an entry port to the central nervous system (CNS). ACE2 receptors
are abundantly expressed on dopamine neurons, which may worsen the prognosis of motor symptoms in Parkinson’s
disease (PD). SARS-CoV-2 may lead to an indirect response via immune-mediated cytokine storms and propagate through
the CNS leading to damage. In this systematic review, we aim to provide thorough analyses of associations between
COVID-19 and neurological outcomes for patients with PD. Methods: Using PRISMA statement 2020, a systematic review
was conducted to isolate confirmed COVID-19 patients and analyze the PD-associated neurological outcomes using the
following databases: PubMed, Science Direct, Google Scholar, and Cochrane databases. The following keywords were used
“COVID19, SARS-CoV-2, Parkinson’s disease, Pandemic, Mortality.” A modified Delphi process was employed. Results:
Of the 355 studies located during the initial round of screening, 16 were included in the final synthesis. Of PD patients
who tested positive for SARS-CoV-2, worsening motor symptoms and other viral-associated symptoms were reported.
These symptoms included bradykinesia, tremors, gait disturbances, delirium and dementia, and severe spasms of arms and
legs. Encephalopathy was presented in 2 of the included studies. Increased mortality rates were identified for hospitalized
patients due to COVID-19 and PD as compared to other patient groups. Conclusion: Patients with PD may experience
substantial worsening of symptoms due to COVID 19. Given the novelty of neurological-viral associations, clinical studies
in the future ought to explore the disease severity and neurological outcomes in COVID-19 positive patients with PD as
compared to non-PD patients, in addition to understanding the role of ACE2 in increased vulnerability to contracting the
infection and as a treatment modality.
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Introduction
At the onset of the coronavirus disease (2019) pandemic on 31
December 2019, many reports found that SARS-CoV-2 primarily caused pneumonia-like symptoms.1 This virus emerged
as a global threat and a public health emergency of imminent
concern across countries worldwide, with exponential transmission capability. As of May 25, 2021, there have been
167 million confirmed cases of COVID-19, with reported
deaths up to 3.47 million globally.2 COVID-19 belongs to a
novel member of the coronaviridae family named SARSCoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).3

1

Research & Academic Affairs, Larkin Health System, South Miami, FL,
USA
2
AMA School of Medicine, Makati, Philippines
3
Research & Publications, Fatima Jinnah Medical University, Lahore, Pakistan
4
Pediatrics & Child Health, The Aga Khan University, Karachi, Pakistan
5
The Research Institute of St. Joe’s Hamilton, Hamilton, ON, Canada
6
Jinan University, Guangzhou, P.R. China
7
Cayetano Heredia Peruvian University, Lima, Peru
8
Neurology, Larkin Community Hospital, South Miami, FL, USA
Corresponding Author:
Azza Sarfraz, Division of Research and Academic Affairs, Larkin Health
System, 7031 SW 62nd Avenue, South Miami, FL 33143, USA.
Email: azza.sarfraz@aku.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use,
reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open
Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

2

Journal of Primary Care & Community Health 

Parkinson's Disease Clinical Manifesations
Motor manifestations

Non-motor
manifestations

Autonomic
manifestations

Figure 1. Clinical manifestations of Parkinson’s disease.

Coronaviruses are enveloped positive single-stranded RNA
viruses, and the 3′ terminal contains structural proteins. The
Spike (S) protein allows the virus to fuse to host cell membranes in proximity to infected and uninfected cells.4 A surge
in the levels of cytokines (TNF-α, IL-6, IL-8, and IL-10) have
been reported, leading to a suppression of T-cell response.5 To
date, a multitude of studies have assessed the role of angiotensin-converting enzyme 2 (ACE2) receptors in the increasing
vulnerability of hosts, however, there is a dearth of analysis on
the role of ACE inhibitors in treating Parkinson’s disease (PD)
patients. A meta-analytical study found that PD is a common
comorbidity in older patients with COVID-19, which is also
associated with poor in-hospital outcomes.6 The results of the
meta-regression further consolidated that mortality from
COVID-19 was statistically associated with age, and not with
gender or dementia, which is key in monitoring PD to minimize infection risks and prevent adverse events.6 In this systematic review, we aim to provide an updated, thorough
analysis of associations between COVID-19 and neurological
outcomes for patients with PD.
Coronavirus disease (2019) has prompted many challenges in global healthcare systems due to its unpredictability
and unique manifestations in (1) pulmonary, (2) neurological,
(3) cardiovascular, (4) gastrointestinal, and (5) hematological
systems. The scientific literature confirms the presence of
SARS-CoV-2 in CSF, in addition to respiratory, fecal, and
blood samples. In about 36.4% of cases, neurological findings have been identified, ranging from dizziness, headache,
hyposmia, hypogeusia, dysphagia, muscle pain, seizures, and
loss of consciousness.7 COVID-19 also influences socializing factors such as the surge in isolation-induced neurological effects, limited social activities possibly leading to short
or long-term neuropsychiatric disorders.
We hypothesize that COVID-19 induced lockdowns,
self-isolation, and the fears associated with contracting disease accentuate neuro-psychiatric problems such as depression and cognition. Figure 1 illustrates motor and non-motor

manifestations in addition to autonomic manifestations that
are pertinent in the assessment of the clinical outcomes of
confirmed positive PD patients. Given the dearth of data,
we aim to provide a comprehensive and updated systematic
review to guide clinical care and practice in understanding
the effects of COVID-19 on Parkinson’s disease.

Methodology
Using the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) 2020 statement, a systematic literature search was performed from December 2019
through May 2021.8 The following set of keywords were
used, employing the Boolean (and/or) logic: “COVID19,”
“SARS-CoV-2,” “Parkinson’s disease,” “Pandemic,”
“Mortality.” We searched the following databases, namely,
PubMed, Cochrane, Science Direct, EMBASE, and Google
Scholar. A modified Delphi approach was utilized to include
studies and ensure that the clinical outcome measures are
identified in a systematic and unanimous order in the
included studies.9 The a-priori Delphi process for systematically analyzing the available data involved 2 rounds of
screening with a final panel feedback round.9 During round
1, 10 questions pertaining to PD and clinical outcome measures were identified using a pre-determined panel of
experts, which was graded on a Likert scale (1-5). In round
2, the top 5 questions were sent to the panel and they were
individually scored by all members. In the panel feedback
round, the prioritized research questions with the final list
and scores were sent to the panel for information sharing.
The PRISMA flowchart is illustrated in Figure 2.

Study Selection
We included studies with confirmed COVID-19 disease
who had a history of Parkinson’s disease. Studies published
with open access availability were included. In total, 355
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Figure 2. PRISMA Flowchart.

studies were located during the initial round of screening.
During this round of screening, all authors scanned the
abstracts and titles independently, which led to the location
of 155 studies. In the second screening round, full-text studies were screened, and 125 articles that met the exclusion
criteria were removed. During the third screening round, 84
studies were screened for eligibility. In total, 35 studies
were excluded as non-PD patient groups were present, 16
studies had incomplete data for sourcing, and 16 of the fulltext studies present with post-COVID-19 PD development,
which met the exclusion criteria. Finally, 16 studies were
included in the qualitative synthesis.

Eligibility Criteria
The inclusion criteria for studies and the target population
consisted of (1) COVID-19 patients with Parkinson’s disease, (2) patients diagnosed with Parkinson’s disease before
COVID-19 infection, (3) age group >21 years old, (4) male
and/or female, and (5) available articles in English language
only. Studies were excluded if they met 1 or more of the
following criteria (1) COVID-19 negative PD patients, (2)
studies on pregnant women, (3) the pediatric population, (4)
crossover study design, and (5) commentaries/perspective
pieces.
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Figure 3. Types of studies included in the systematic review.

Data Extraction and Synthesis
The following data were extracted from eligible studies:
serial number, author and year, study design, sample size,
gender, age, comorbidities, disease duration, PD outcomes,
COVID-19 associated symptoms. A shared spreadsheet was
used to input data, which was extracted independently by 3
authors for analysis and cumulative result interpretation
(V.J., D.A., Z.S.). The fourth reviewer (A.S.) solved any
discrepancies in data extraction and reach a consensus in
case of any disagreements.
Quality assessment was conducted by 2 authors (V.J. and
Z.S.), who independently assessed the (1) criteria of diagnosis
of COVID-19 patients, (2) confirmed diagnosis of PD before
the COVID-19 pandemic, (3) PD sequelae in the included
studies. A descriptive analysis was conducted and presented
for the included studies. Percentages and means were presented. Frequent outcomes were reported if they have a frequency of at least 5% or more in the included studies. The
term PD complications were based on the motor, non-motor,
and autonomic complications mentioned in Figure 1.
No funding was obtained for this study.

Male gender was predominant in 10 studies,10-19 and
female gender was the predominant 1 in 6 studies.18,20-24
Of the available patient data, the cumulative mean of
age in years of included patients was 76.9 years. The average disease duration spanned 11 years before the incidence
of COVID-19 disease. Majority of the included patients
presented with comorbid conditions, comprising of
hypertension,10,14,16,17,21,22,24,25 diabetes,11,13,17,19-22 obesity,10
dyslipidemia,22
cardiovascular
disease,10,11,15,16,20-22,25
10,16,25
immunocompromised,
COPD,10,14,15,19 asthma,19
chronic renal, and liver diseases.19,20,25 Of the PD patients
that were tested and positive infection with SARS-CoV-2,
worsening of motor symptoms10-12,15-17,19,20,22,24 including
bradykinesia, tremors, gait disturbances, delirium, and
dementia14,20 were noted; severe spasms of the arms and
legs23 were found, with individual study percentages of
motor symptoms ranging from 19% to 100%, along with
other COVD-19 symptoms. Encephalopathy was also one
of the major symptoms, which presented in 2 (12.5%) of
the 16 studies.20,24 Mortality rates for PD patients with
COVID-19 who were hospitalized ranged from 5.7% to
100%.10-17,19-23,25

Results

Discussion

Of the 355 studies identified during the first round of
screening, 16 studies comprising, 7 (43.8%) were case
reports and case series, 4 (25%) case-control studies, 2
(12.5%) cross-sectional, 2 (12.5%) cohort, and 1 (6.25%)
retrospective study were added (Figure 3).10-25 In total, a
synthesis of 1290 PD patients with COVID-19 and the characteristics of all included studies are presented in Table 1.

To our best understanding, this is the first systematic review
to assess clinical outcomes of Parkinson’s disease (PD) in
confirmed COVID-19 patients with a pre-pandemic PD
diagnosis. Wide varieties of neurological consequences have
been reported in scientific literature among COVID-19 positive patients.26-34 Neurological symptoms comprised of the
following include those associated with core dysfunction
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Case report

Cross sectional

Cohort,
observational

Case report

Case series

Cohort

Lo Monaco
et al13
Fasano et al14

Filatov et al15

Brown et al16

Kobylecki et al17

Lo Monaco
et al18

Antonini et al19

Vignatelli et al20

4

6

7

8

9

10

11

Case-control
survey

Case report
Case series

Zhai et al12

3

5

Case-control

Del Prete et al11

2

Case-control

Study design

Cilia et al
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Authors

1

No

696 PD
184
parkinsonism
control 8590

10

1

58

51

1

105

2
5

7 cases
14 control

12 cases
36 control

Sample (N) PD

Table 1. Characteristics of Included Studies.

58.8 and PD
57.1
parkinsonism
58.2 control

60%

0%

62.5%

47%

52.4%

50%
66.6%

57.2% cases
57.2% control

41.7% cases
41.7% controls

Males, %

75 PD 80.5 PS
Control 76.0

78.3

58

78.3

65

74

70.5

77.5
74.2

75.7 years cases
vs 75 years
control

65.5 years cases
66.3 years control

Age, Mean

PD and PS
22.6% cardiomyopathies
14.6% Cerebrovascular disease
8.5% Chronic pulmonary disease
0.3% Liver disease
5%Renal disease
10% DM
8.5% malignancies

Diabetes Orthostatic hypotension
CHF
COPD
Asthma
IHD, CKD, dementia, osteoporosis
anxiety disorder

NA

Diabetes 8%
HTN 38%

Immunocompromised 22%
Heart Disease 20%
HTN 25%
Lung disease 14%

Atrial fibrillation
Cardioembolic stroke
COPD

Obesity 18.1%
HTN 41.9%
COPD 5.6%
Diabetes 7.6%
Cancer .9%

HTN
20% chronic Renal failure
20% diabetes hypertension

Cases: 71.5% HTN
42.8% diabetes
28.5% cardiomyopathy
14.2% malignancies

8.3% COPD
33.3 HTN
8.3% obesity
8.3% cardiopathy
16.7% cancer
8.3% immuno-compromised

Comorbidities %

NA

12.7 years

8 years

9.5

0–3 years , 21
3–6 years, 12
6–9 years, 9
>9 years, 9

Hospitalization
0.6% PD
3.3% PS
0.7% control
Mortality rate
35.1% in all
group

40% mortality
rate

NA

22.4% Mortality
rate

9.8% hospitalized
3.9% ICU
2%ventilator

ICU
hospitalization
Poor prognosis

17.1%
hospitalized
5.7% mortality

9.9 years

NA

100%
20% case fatality

13% mortality
14% case fatality

50% affected by
COVID-19
(cases group);
0% affected
by COVID-19
in control
group, 8.3%
hospitalized

Outcomes

22 years
NA

9.3 years cases
8.9 years control

6.3 years cases
6.1 years control

Disease duration,
mean

(continued)

PD: 72.8%Tremor
80.4% Bradykinesia
81.6% Clinical features at onset
unilateral
PS: 52.5% Tremor
89.2% Bradykinesia
52.5% Clinical features at onset
unilateral

Worsening of mobility with fall
Worsening of motor symptoms
Worsening of anxiety

Severe spasms of arms and legs.

69% Delirium
54% Dementia

55% worsening
18% new PD symptoms

Encephalopathy

100% worsening
60% worsening

30% worsening

Worsening of motor symptoms

PD related symptoms with COVID %
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Case control

Case report

Santos-García
et al22

Sainz-Amo
et al23

Li et al24

de Marcaida
et al25

13

14

15

16

Retrospective

Cross-sectional

Multiple case
reports

Artusi et al21

12

Study design

Authors

No

Table 1. (continued)

36, 22 PD

1

Case: 33
Control:172

15

8

Sample (N) PD

64%

Female

5 59

47.1%

62.5%

Males, %

74.5

85

Case:75.9
Control: 73.9

76.3

74

Age, Mean

HTN cardiovascular disease, renal
disease, diabetes, chronic lung
disease, immunosuppression

HTN
Stroke

36% Dementia

26.7% HTN
20% DM
64.3% dyslipidemia
13.3% cardiomyopathy
6.7% valvular cardiomyopathy
20% cardiac arrhythmia
6.7% cardiac insufficiency
14.3% pulmonary disease
6.7% smoking

HTN
diabetes, depression
Lung neoplasm
Atrial fibrillation

Comorbidities %

16.2 years

6 years
67%
hospitalization
36% mortality

54%
hospitalization
21% mortality
rate

33.3%
Hospitalized

NA

Case: 8.9
Control8.5

75% mortality
rate

Outcomes

12.2 years

Disease duration,
mean

75% Alteration mental status
19% worsening of their Movement
abnormality
31% worsening mobility

Worsening motor symptoms.
Encephalopathy

NA

65.7% worsening of symptoms
47.7% bradykinesia
41.4% sleep problems
40.7% rigidity
34.5% gait disturbances
31.3% anxiety
28.5% pain
28.3% fatigue
27.6% Depression
20.8% tremor

50% worsening of PD symptoms

PD related symptoms with COVID %

Jaiswal et al
(fatigue, headache, confusion, stroke,35 dizziness, syncope,36
seizure, anorexia, and insomnia),37-39 central-peripheral mixture (Guillain Barre syndrome),40 enteric, or peripheral nervous systems dysfunction (anosmia, ageusia, myoclonus,41
neuropathic pain, and myalgia).42 The increase in hospital
admission and mortality rates in PD and other chronic neurological diseases during the COVID-19 pandemic is of
imminent concern as the long-term sequelae are currently
undetermined. Most neurological diseases, including PD,
are dose-dependent on prescribed medications for symptomatic management. With the compounded neuropsychiatric
symptoms due to social isolation and outpatient clinics, temporarily being suspended and irregular visits, these are causative in worsening PD symptoms among COVID-19
patients.43
In this systematic review, we included studies with
COVID-19 positive patients with a prior history of
Parkinson’s disease. The most common manifestations due
to COVID-19 in PD patients were found to be motor dysfunction. The majority of the studies showed a common
motor deficit domain in the range of moderate to severe.
Some of the patients presented with delirium, dementia, and
encephalopathy among other COVID-19 complications.
We posit that this may be related to the ACE2 mechanism in
the nervous system. It is postulated that SARS-CoV-2 enters
the cell, increases the activity of T cells, causing vasodilation, thrombosis, and hypoxemia, which may then lead to
stroke and seizures. One theory supports the effect of the
virus by stating that SARS-COV-2 attacks ACE 2 receptors
in a multi-organ manner, targeting the brain. A study found
that ACE2 receptors act locks on cells and the SARS-CoV-2
spike proteins act rapidly multiply on entering the cells.
These ACE2 receptors control tissues in the eye, reproductive system, renal-excretory, digestive, and respiratory system, and 21 different regions of the brain, which require
further deliberation in PD patients.44
We found that the average age of all participants was
76.9 years with a male predominance, in addition to a prior
disease duration of 11 years. The majority of the patients
reported the presence of other comorbidities, of which the
following were the most common: hypertension, diabetes,
obesity, dyslipidemia, cardiovascular disease, immunocompromised, COPD, asthma, chronic renal, and chronic liver
diseases. Documented COVID-19 neurological complications include stroke, especially in younger patients, reflecting the hypercoagulable state, leukoencephalopathy, and
hemorrhagic leukoencephalopathy. Although direct encephalitis was documented, it is rare but does occur. Further, cranial neuropathies are also infrequent but include the loss of
sense of smell (cranial nerve 1) and Bell’s palsy (cranial
nerve 7).45 There have been neurocognitive signs, particularly in older age groups that warrant further associations to
PD symptoms, clinical care, and management in the short
and long term.
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The COVID-19 pandemic has led to adaptive changes to
acute PD care. A majority of multidisciplinary care is performed remotely, and the reallocation of resources has taken
place in an ad hoc fashion across many centers.46 The acute
care of PD has been facilitated using telemedicine, albeit
with certain limitations such as remotely assessing mood
and anxiety, cognition, postural reflexes, and rigidity.46
Other adaptive strategies in treating acute PD during the
COVID-19 pandemic include remote deep brain stimulation (DBS) programming-based tools that may evaluate
patient symptoms online, which have shown to improve the
motor symptoms among PD patients during quarantine.46
The signs and symptoms of COVID-19 in patients with PD
may appear 2 to 14 days post-exposure, and without any
cure, the several FDA approved vaccines may protect from
hospitalization or severe illness. In the United States,
BioNTech/Pfizer, Johnson & Johnson’s, and Moderna have
been widely distributed in the event of viral exposure.47
Data also shows that the vaccines are safe and beneficial to
patients with Parkinson’s disease. While patients with PD
may experience side effects such as temporary worsening of
pre-existing Parkinson’s symptoms, vaccines are believed
to not cause any long-term changes to PD signs and symptoms.47 To improve compliance to life post-COVID-19, it is
essential that adapting to life with PD and viral infection
incorporates daily hygiene measures. Symptoms such as
altered speech, poor balance, restlessness, and fatigue may
lead to poor adherence to daily hygiene. Through PD tailored home equipment, adjustments, and routine habit integration, patients may be able to manage the disease well
during and post the COVID-19 pandemic.

Limitations
We had certain limitations. The first included the presence
of confounder factors. These related to the finding that multiple studies of patients with elderly PD patients had other
comorbidities, possibly leading to an overrepresentation of
findings. Secondly, the duration of PD and the severity of
the pre-pandemic symptoms possibly influenced the synthesis of clinical outcomes due to COVID-19 infection.
Thirdly, pertinent information, including prior and current
medications and compliance to treatment was lacking, leading to a lack of generalized recommendations for PD and
COVID-19 clinical care. Albeit, our findings are pertinent
for long-term PD patients with acquired COVID-19
infection.

Conclusion
COVID-19 has a peaked mortality rate in older age groups,
compounded with comorbid conditions. The CNS is
increasingly susceptible to SARS-CoV-2, deteriorating
neurological findings, particularly in patients with PD. We
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find that motor dysfunction, delirium, dementia, severe
spasms of arms and legs, and encephalopathy are pertinent
clinical findings in PD patients and ought to be addressed in
current care and practice. The susceptible groups of
COVID-19 positive patients with a history of PD are elderly
males with 10 years or longer duration of illness and other
comorbid conditions. It is still unclear how SARS-CoV2
affects the long-term health of the nervous system in PD
patients. It is recommended that healthcare practitioners
address diminished neurological outcomes, changes in-hospital stay, and raised mortality in PD patients.
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